Trial Profile
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN): The KEO Trial
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms The KEO Trial
- 18 Apr 2019 Planned End Date changed from 1 Jun 2020 to 7 Nov 2018.
- 18 Apr 2019 Planned primary completion date changed from 1 Jun 2020 to 7 Nov 2018.
- 18 Apr 2019 Planned initiation date changed from 1 Nov 2018 to 22 Jan 2018.